Avastin, Tamiflu depress Roche sales by 7%

Poor performance from its cancer star Avastin and falloff from last year's pandemic sales of Tamiflu pushed Roche's sales down by 7 percent to $12.1 billion, below analysts' estimates; the company expects global pricing pressures to cut revenue growth by two percentage points this year. Article | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.